Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections
- PMID: 16858182
- PMCID: PMC1602153
- DOI: 10.1097/01.sla.0000230024.84190.a8
Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections
Abstract
Objective: To compare the safety and efficacy of sequential intravenous (IV) to oral (PO) moxifloxacin treatment against a standard antimicrobial regimen of IV piperacillin-tazobactam followed by PO amoxicillin-clavulanate for the treatment of adults with complicated intra-abdominal infection (cIAI).
Summary background data: cIAIs are commonly due to mixed aerobic and anaerobic bacteria and require both source control and broad-spectrum antibiotic therapy.
Methods: A prospective, double-blind, randomized, phase III comparative trial. Patients with cIAI were stratified by disease severity (APACHE II score) and randomized to either IV/PO moxifloxacin (400 mg q24 hours) or comparator (IV piperacillin-tazobactam [3.0/0.375 g q6 hours] +/- PO amoxicillin-clavulanate [800 mg/114 mg q12 hours]), each for 5 to 14 days. The primary efficacy variable was clinical cure rate at the test-of-cure visit (days 25-50). Bacteriologic outcomes were also determined.
Results: : Of 656 intent-to-treat patients, 379 (58%) were valid to assess efficacy (183 moxifloxacin, 196 comparator). Demographic and baseline medical characteristics were similar between the 2 groups. Clinical cure rates at test-of-cure were 80% (146 of 183) for moxifloxacin versus 78% (153 of 196) for comparator (95% confidence interval, -7.4%, 9.3%). The clinical cure rate at test-of-cure for hospital-acquired cIAI was higher with moxifloxacin (82%, 22 of 27) versus comparator (55%, 17 of 31; P = 0.05); rates were similar for community-acquired infections (80% [124 of 156] versus 82% [136 of 165], respectively). Bacterial eradication rates were 78% (117 of 150) with moxifloxacin versus 77% (126 of 163) in the comparator group (95% confidence interval, -9.9%, 8.7%).
Conclusions: Once daily IV/PO moxifloxacin monotherapy was as least as effective as standard IV piperacillin-tazobactam/PO amoxicillin-clavulanate dosed multiple times daily for the treatment of cIAIs.
Similar articles
-
A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections.J Antimicrob Chemother. 2011 Nov;66(11):2632-42. doi: 10.1093/jac/dkr344. Epub 2011 Sep 6. J Antimicrob Chemother. 2011. PMID: 21896561 Free PMC article. Clinical Trial.
-
Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate.J Antimicrob Chemother. 2007 Aug;60(2):370-6. doi: 10.1093/jac/dkm130. Epub 2007 Jun 6. J Antimicrob Chemother. 2007. PMID: 17553812 Clinical Trial.
-
Efficacy and safety of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of diabetic foot infections: results of the RELIEF study.Infection. 2013 Feb;41(1):175-86. doi: 10.1007/s15010-012-0367-x. Epub 2012 Nov 23. Infection. 2013. PMID: 23180507 Free PMC article. Clinical Trial.
-
Piperacillin/tazobactam: a pharmacoeconomic review of its use in moderate to severe bacterial infections.Pharmacoeconomics. 2001;19(11):1135-75. doi: 10.2165/00019053-200119110-00006. Pharmacoeconomics. 2001. PMID: 11735679 Review.
-
The treatment of severe intra-abdominal infections: the role of piperacillin/tazobactam.Intensive Care Med. 1994 Jul;20 Suppl 3:S35-8. doi: 10.1007/BF01745249. Intensive Care Med. 1994. PMID: 7962987 Review.
Cited by
-
Essentials for selecting antimicrobial therapy for intra-abdominal infections.Drugs. 2012 Apr 16;72(6):e17-32. doi: 10.2165/11599800-000000000-00000. Drugs. 2012. PMID: 22480338 Free PMC article.
-
In vitro activities of moxifloxacin and tigecycline against bacterial isolates associated with intraabdominal infections at a medical center in Taiwan, 2001-2006.Eur J Clin Microbiol Infect Dis. 2009 Dec;28(12):1437-42. doi: 10.1007/s10096-009-0801-x. Epub 2009 Sep 8. Eur J Clin Microbiol Infect Dis. 2009. PMID: 19763644
-
Emerging treatment options for acute bacterial skin and skin structure infections: focus on intravenous delafloxacin.Infect Drug Resist. 2018 Apr 4;11:479-488. doi: 10.2147/IDR.S142140. eCollection 2018. Infect Drug Resist. 2018. PMID: 29670380 Free PMC article. Review.
-
Fluoroquinolone resistance during 2000-2005: an observational study.BMC Infect Dis. 2008 May 24;8:71. doi: 10.1186/1471-2334-8-71. BMC Infect Dis. 2008. PMID: 18501015 Free PMC article.
-
Amoxicillin-Clavulanate Breakpoints Against Enterobacterales: Rationale for Revision by the Clinical and Laboratory Standards Institute.Clin Infect Dis. 2024 Aug 16;79(2):516-523. doi: 10.1093/cid/ciae201. Clin Infect Dis. 2024. PMID: 38626241 Free PMC article.
References
-
- Solomkin JS, Mazuski JE, Baron EJ, et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis. 2003;37:997–1005. - PubMed
-
- Condon RE, Wittmann DH. Intraabdominal infections. In: Gorbach S, Blacklow N, Bartlett JG, eds. Infectious Diseases, 2nd ed. Philadelphia: Saunders, 1998:793–800.
-
- Levison ME, Bush LM. Peritonitis and other intra-abdominal infections. In: Mandell D, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases, 5th ed. Philadelphia: Churchill Livingstone, 2000:821–856.
-
- Nathens AB, Rotstein OD. Antimicrobial therapy for intra-abdominal infection. Am J Surg. 1996;172(suppl):1–6. - PubMed
-
- Berne TV, Yellin AW, Appleman MD, et al. Antibiotic management of surgically treated gangrenous or perforated appendicitis: comparison of gentamicin and clindamycin versus cefamandole versus cefoperazone. Am J Surg. 1982;144:8–13. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical